Robert Barrie

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

Robert Barrie Novo Nordisk, the owner of the Ozempic and Wegovy GLP-1 drugs, has announced a deal to work with a Californian biotech firm on a weight-loss implant.

AstraZeneca has acquired the global rights to Dizal Pharmaceutical's Zegfrovy (sunvozertinib), marking the drugmaker's second venture to China in a month in search of new assets.

Closing the gender gap could boost the global economy by at least $1tn annually by 2040.

Closing the gender gap could boost the global economy by at least $1tn annually by 2040.

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.

The pharma industry welcomed the pledge, which marked the first-time drug IP has explicitly been stated in a free trade agreement

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

The therapies' availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.

Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.